If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs ...
The ITAT Delhi held that the Revenue could not substitute the assessee's consistent method of revenue recognition with the Percentage of Completion Method for only one assessment year. It deleted the ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果